Metadifluoromescaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Metadifluoromescaline (MDFM), also known as 3-(difluoromethoxy)-4,5-dimethoxyphenylethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[3][1][2] It is a difluorinated derivative of mescaline.[3][1][2] It has a dose of 85 mg or more orally and a duration of approximately 8 hours.[1][2] The drug is described as being slightly more potent than mescaline.[3] However, it is said to produce some rather unpleasant effects at the highest assessed dose of 85 mg, including physical discomfort, listlessness in the days after taking the drug, and a practical absence of hallucinogenic effects at this dose.[3][1] MDFM is a partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets.[2][1][3] It was first described in the scientific literature by Daniel Trachsel in 2012.[1][3][2] Subsequently, its pharmacology was studied in greater detail in 2021.[2] It is not a controlled substance in Canada as of 2025.[4]
- None
 | |
| Clinical data | |
|---|---|
| Other names | MDFM; 3-(Difluoromethoxy)-4,5-dimethoxyphenylethylamine; 3,4-Dimethoxy-5-(difluoromethoxy)phenethylamine |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C11H15F2NO3 |
| Molar mass | 247.242 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
